Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapse-remitting Multiple Sclerosis”

Showing 20 of 0 results

Large-scale testing (Phase 3)Study completedNCT00441103
What this trial is testing

Evaluate Rebif® New Formulation (Interferon-beta-1a) in Relapsing Remitting Multiple Sclerosis

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Merck KGaA, Darmstadt, Germany 180
Large-scale testing (Phase 3)Looking for participantsNCT06408259
What this trial is testing

Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Bristol-Myers Squibb 194
Not applicableStudy completedNCT06987994
What this trial is testing

The Effect of Virtual Reality on Fatigue and Functional Capacity in Patients With MS

Who this might be right for
Multiple SclerosisMultiple Sclerosis (MS) - Relapsing-remittingVirtual Reality
Istinye University 30
Not applicableStudy completedNCT04468165
What this trial is testing

Effectiveness and Safety of Generic Delayed-Release Dimethyl Fumarate (Sclera® or Marovarex ®, Hikma) in Routine Medical Practice in the Treatment of Relapsing-Remitting Multiple Sclerosis in MENA Region

Who this might be right for
Relapsing Remitting Multiple Sclerosis
Hikma Pharmaceuticals LLC 160
Large-scale testing (Phase 3)Study completedNCT00883337
What this trial is testing

A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
Sanofi 324
Large-scale testing (Phase 3)Study completedNCT02727907
What this trial is testing

Study of Efficacy and Safety of Drugs BCD-033 and Rebif for Treatment of Patients With Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
Biocad 163
Not applicableWithdrawnNCT01539395
What this trial is testing

A Cross-Sectional Study of MSDx Complex 1 as a Marker for Active Disease in Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
MSDx, Inc.
Not applicableStudy completedNCT03157830
What this trial is testing

Evaluating the Efficacy and Safety of Transitioning Patients From Natalizumab to Ocrelizumab

Who this might be right for
Relapsing Remitting Multiple Sclerosis
Providence Health & Services 43
Large-scale testing (Phase 3)Active Not RecruitingNCT05201638
What this trial is testing

Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Immunic AG 1,100
Large-scale testing (Phase 3)Study completedNCT02634307
What this trial is testing

ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1

Who this might be right for
Multiple Sclerosis
Biogen 1,057
Early research (Phase 1)Study completedNCT02517788
What this trial is testing

Phase I BP Interferon (IFN) Beta-004

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Centre Hospitalier Universitaire Vaudois 24
Testing effectiveness (Phase 2)Study completedNCT03381170
What this trial is testing

An Extension of the TG1101-RMS201 Trial

Who this might be right for
Relapsing Remitting Multiple Sclerosis
TG Therapeutics, Inc. 48
Post-approval studies (Phase 4)Ended earlyNCT05532163
What this trial is testing

Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous (SC) Natalizumab in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Biogen 1
Post-approval studies (Phase 4)WithdrawnNCT02568111
What this trial is testing

Brimonidine Tartrate for the Treatment of Injection Related Erythema

Who this might be right for
Relapsing-Remitting Multiple Sclerosis (RRMS)
Biogen
Not applicableUnknownNCT06159712
What this trial is testing

Comparative Study of High-Efficacy Disease Modifying Treatment of Relapsing Multiple Sclerosis

Who this might be right for
Relapsing Remitting Multiple Sclerosis
University of Aarhus 200
Large-scale testing (Phase 3)Study completedNCT02746744
What this trial is testing

RItuximab Versus FUmarate in Newly Diagnosed Multiple Sclerosis.

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Anders Svenningsson 200
Not applicableStudy completedNCT00232193
What this trial is testing

Safety/Effectiveness of Adding Monthly Dexamethasone to Weekly Avonex for MS

Who this might be right for
Relapsing-remitting Multiple SclerosisClinically Isolated Syndrome
Providence Multiple Sclerosis Center 40
Large-scale testing (Phase 3)WithdrawnNCT00429442
What this trial is testing

Simvastatin as an add-on Treatment to Copaxone for the Treatment of Relapsing Multiple Sclerosis

Who this might be right for
Relapsing Remitting Multiple Sclerosis
Anna Tsakiri
Early research (Phase 1)Study completedNCT05181215
What this trial is testing

Bioequivalence Study of Bafiertam 190 mg and Vumerity® 462 mg Delayed-Release Capsules in Fasting Healthy Subjects

Who this might be right for
Relapsing Remitting Multiple Sclerosis
Banner Life Sciences LLC 46
Not applicableEnded earlyNCT00919217
What this trial is testing

Exploratory Study on the Timing of Multiple Sclerosis (MS) Symptoms

Who this might be right for
Relapsing Remitting Multiple Sclerosis
University of Louisville 80
Next Page

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation